Acute Oral Toxicity Assessment of Xlivpro Premix in Wistar Rats: A Liver Protective Herbal Premix

The study was aimed to evaluate the acute oral toxicity and safety profile of Xlivpro Premix in accordance with OECD-423 guidelines. Experimental study involving the assessment of toxic effects and mortality in adult Wistar rats following oral administration of Xlivpro Premix. The study was conducted at the Department of Veterinary Pharmacology and Toxicology, Post Graduate Institute of Veterinary and Animal Sciences (PGIVAS), Akola, Maharashtra, India over a period of 14 days. Six healthy adult Wistar rats (113–134 grams) were administered Xlivpro Premix orally at doses of 300 mg/kg and 2000 mg/kg body weight. Observations for toxic effects and mortality were recorded for 14 days. Blood biochemical parameters including AST, ALT, ALP, and creatinine were measured. At the end of the study, histopathological examinations of vital organs including the heart, liver, kidneys, and lungs were performed. No toxic effects or mortality were observed in Xlivpro-treated rats during the experimental period. Changes in body weight over the 14-day period remained within normal range. Biochemical parameters and histopathological evaluations indicated no significant abnormalities. The LD50 of Xlivpro Premix exceeded 2000 mg/kg, confirming the safety of formulation.